Evidence map›Paper›PMID 40163182›Full record

ArticleAnnals of hematology2025

Correction to: Evolution of frontline treatment for multiple myeloma: clinical investigation of quadruplets containing carflzomib and antiCD38 monoclonal antibodies.

Luciano J Costa, Francesca Gay, Ola Landgren, María-Victoria Mateos, Philippe Moreau, Cyrille Touzeau, Franziska Ertel, Ian McFadden, Rani Najdi, Katja Weisel

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Luciano J CostaDivision of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham Hospital, 1802 6Th Avenue South, Birmingham, AL, 35294, USA. ljcosta@uabmc.edu.ORCID http://orcid.org/0000-0001-5362-2469
Francesca GayAOU Città Della Salute E Della Scienza Di Torino, University of Torino, Turin, Italy.ORCID http://orcid.org/0000-0002-8619-412X
Ola LandgrenDivision of Myeloma, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL, USA.ORCID http://orcid.org/0000-0001-6485-4839
María-Victoria MateosUniversity Hospital Salamanca/IBSAL/CIC/Ciberonc, Salamanca, Spain.ORCID http://orcid.org/0000-0003-2390-1218
Philippe MoreauThe Hematology Clinic, University Hospital Hôtel-Dieu, Nantes, France.ORCID http://orcid.org/0000-0003-1780-8746
Cyrille TouzeauThe Hematology Clinic, University Hospital Hôtel-Dieu, Nantes, France.ORCID http://orcid.org/0000-0003-0275-2575
Franziska ErtelAmgen GmbH, Munich, Germany.ORCID http://orcid.org/0009-0006-6970-303X
Ian McFaddenAmgen Inc, Thousand Oaks, CA, USA.ORCID http://orcid.org/0009-0004-7488-8804
Rani NajdiAmgen Inc, Thousand Oaks, CA, USA.
Katja WeiselDepartment of Oncology, Hematology and BMT, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID http://orcid.org/0000-0001-9422-6614

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40163182
PMCPMC12031826

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.